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Nowadays, the incidence of endometrial cancer is rising, especially of high-grade endometrial tumours. Recently, the FIGO
classiﬁcation of endometrial cancer has changed worldwide. Besides that, treatment strategies are changing. The purpose of this
study was to analyse the adherence to the national guidelines of cancer treatment and to analyse patterns of disease relapse and
survival. We focused on a group of patients (n = 191) with endometrial cancer, in a time period in which new treatment strategies
are not yet completely implemented. Because of multiple upcoming changes in patient characteristics, tumour classiﬁcation, as
well as treatment regimens, a more heterogeneous cohort of patients diagnosed with endometrial cancer will appear. From now
on, all those changes will have their eﬀects on the followup of conventional endometrial cancer treatment. In our opinion, it is,
therefore, valuable to have the current, more homogenous, cohort clearly described.
1.Introduction
Endometrial cancer is the most common cancer of the
female genital tract in western countries [1]. Each year,
approximately 17.8 per 100,000 women are diagnosed hav-
ing endometrial cancer in the Netherlands [2]. Although
endometrial cancer has the lowest mortality rates of all
gynaecologic malignancies, still about 400 women yearly
die from the disease in this country [3]. Nowadays, the
incidence is rising due to an earlier diagnosis, a prolonged
life expectancy, and an increasing incidence of risk factors
such as nulliparity, obesity, and diabetes mellitus. Impor-
tant prognostic factors are tumour stage, histopathology,
histological grade, and depth of myometrial invasion [4, 5].
Recently, the FIGO stages of endometrial cancer have been
revised worldwide [6, 7]. Besides that, treatment strategies
are changing. The indications for adjuvant chemotherapy in
cases of endometrial cancer are increasing and the mainstay
of treatment is no longer (solely) total abdominal hysterec-
tomy(TAH)andbilateralsalpingo-oophorectomy(BSO)per
laparotomy. Laparoscopic surgery has been proven to be
safe and will become the treatment of choice in low-stage
endometrial cancers [8–12].
The purpose of this study was to analyse the adherence to
the(yetoutdated)nationalprotocolsofcancertreatmentand
to analyse patterns of disease relapse and survival in patients
having endometrial cancer in our hospital. We focused on
a group of 191 patients with endometrial cancer in a time
period during which new treatment strategies are not yet
completely implemented.
2. Methods
A retrospective analysis was performed on all patients having
endometrial cancer (n = 191), diagnosed between 2002 and
2010 in a Dutch teaching hospital in the south of the
Netherlands. Patients and tumour characteristics were ret-
rospectively obtained from hospital records. In the study
period, patients with endometrial carcinoma were diagnosed
according to the FIGO classiﬁcation of 1988. Surgical
and adjuvant treatment was performed according to the
Dutch guidelines for endometrial carcinoma. We excluded
patients with a sarcoma of the corpus uteri. The followup
lasted till January 2011. According to national guide-
lines, the intention of curative treatment for endometrial
cancer is a total abdominal hysterectomy with bilateral2 ISRN Obstetrics and Gynecology
salpingo-oophorectomy (BSO). Adjuvant radiation- and/or
chemotherapy were given based on the risk factors advised
in the Dutch national guidelines of 2000. Radiation therapy
was either vaginal brachytherapy alone or in combination
with external beam radiation therapy (EBRT), depending on
the FIGO stage [13, 14]. For the analysis of survival, we used
the overall survival (OR) and disease-speciﬁc survival (DSS).
In addition, the recurrence-free survival was calculated.
Recurrence-free interval was deﬁned as the time from
surgical staging to the ﬁrst evidence of recurrence (clinical,
histological or radiological recurrence). The location of
the recurrence was divided into three groups: (1) local
recurrences of the vaginal vault, (2) regional recurrences in
the distal vagina, pelvic cavity or pelvic lymph nodes, (3)
distant metastasis. Survival analysis was performed using
Kaplan-Meier curves. Diﬀerences between survival curves
were assessed using the Mantel-Cox test. A P-value of < 0.05
was considered to be signiﬁcant.
3. Results
A total of 191 patients were diagnosed having endometrial
cancer. Thirteen patients (6.8%) were diagnosed in 2002,
20 (10.5%) in 2003, 35 (18.3%) in 2004, 30 (15.7%) in
2005, 17 (8.9%) in 2006, 18 (9.4%) in 2007, 34 (17.8%)
in 2008, and 24 (12.6%) in 2009. The median age at initial
diagnosis was 66.9 years (range 40–94 years). The mean time
to followup was 37.6 months (range; 0–82 months; median
34.0 months).
3.1. FIGO Stage. The majority of patients (n = 150; 78.5%)
were diagnosed having FIGO stage I disease (IA in 33
(17.3%); IB in 78 (40.8%); IC in 39 (20.4%)). Ten patients
(5.2%) were diagnosed having stage II disease (IIA in 3
(1.6%); IIB in 7 (3.7%)).
A total of 21 women (11.0%) were diagnosed having
stage III disease (IIIA in 16 (8.4%); IIIB in 1 (0.5%); IIIC in
4 (2.1%)). Four patients (2.1%) were diagnosed having stage
IV disease (all IVB).
Twenty patients (10.5%) died of endometrial carcinoma.
Of all deaths, 3 (15.8%) were diagnosed having FIGO stage
IB; 5 (26.3%) in IC, 5 (26.3%) in IIIA; 3 (15.8%) in IVB;
1 patient (5.3%) in the stages IIB, IIIB, and IIIC. Twenty-
one patients (11.1%) died of causes other than endometrial
carcinoma.
The overall 5-year survival was 77.5% in FIGO stage I;
72.5% in FIGO stage II; 51.7% in FIGO stage III; 25% in
FIGO stage IV disease (Table 1). The disease-free survival in
FIGO stage I was 91.0%; in FIGO stage II 75.0%; in FIGO
stage III 59.6%. The disease-speciﬁc survival was 92.6% in
FIGO stage I and 80% in FIGO stage II disease (Figure 1). In
FIGO stage III and IV, the disease-speciﬁc survival was equal
to the overall survival. Overall and disease-speciﬁc survival
in FIGO stage I was signiﬁcantly better than in FIGO stage
III and IV (P<0.033).
3.2. Tumour Type and Grade. Adenocarcinoma of the
endometrium was present in 165 patients (86.4%), papillary
serous tumour in 18 (9.4%). Clear cell and mucinous
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Figure 1: 5-year disease-speciﬁc survival of n = 191 patients
with endometrial cancer, divided by FIGO Stage (1988). Period of
diagnosis 2002–2009.
Table 1: 5-year survival rates of n = 191 patients with endometrial
carcinoma diagnosed between 2002 and 2009. Subdivided into
histological tumour type, FIGO stage and histological tumour
grade.
OSa DSSb DFSc
Histology
Endometrioid 73.5% 87.7% 89.2%
Papillary serous 59.6% 59.6% 68.6%
Clear celld 40.0% 80.0% 60.0%
FIGO
Stage I 77.5% 92.6% 91.0%
Stage II 72.5% 80.0% 75.0%
Stage III 51.7% 51.7% 59.6%
Stage IV 25.0% 25.0% —
Tumour grade (within FIGO stage I
endometrioid)
Grade 1 90.7% 96.0% 92.4%
Grade 2 74.5% 93.1% 90.7%
Grade 3 59.8% 84.1% 88.2%
a:5 - y e a ro v e r a l ls u r v i v a l .
b: 5-year disease-speciﬁc survival.
c: 5-year disease-free survival.
d: maximum follow-up: 46 months.
tumours were present in, respectively, 6 (3.1%) and 2 (1.0%)
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Figure 2: 5-year disease-speciﬁc survival of n = 191 patients with
endometrial cancer, divided by histologic tumour type. Period of
diagnosis 2002–2009.
adenocarcinomas (137 (86.2%) as opposed to 8 (44.4%) in
papillary serous tumours).
Ofalltumours,69(36.1%)weregrade1,69(36.1%)were
grade2,and50(26.2%)weregrade3tumours.InFIGOstage
III, the percentage of grade 3 tumours was higher than in
FIGO stage I disease (grade I, II, and III in FIGO stage I was
41.3%, 38.0%, and 20.7% as opposed to 14.3%, 33.3%, and
52.4% in FIGO stage III). In stage IV, all tumours were high
grade.
The overall 5-year survival was 73.5% in endometrioid
adenocarcinomas and 59.6% in papillary serous tumours.
The disease-speciﬁc survival in endometrioid tumours was
87.7% and in serous tumours 59.6% (Figure 2). The disease-
free survival was 89.2% and 68.6%, respectively. Both
disease-speciﬁc and disease-free survival curves were signif-
icantly better in endometrioid tumours (P = 0.002 and
P = 0.02, resp.).
In FIGO stage I adenocarcinomas, the overall 5-year
survival in grade 1 tumours was 90.7%, 74.5% in grade 2,
and in 59.8% grade 3 tumours. Disease-speciﬁc survival was
96.0% in grade 1 tumours, 93.1% in grade 2 tumours, and
84.1% in grade 3 tumours (Figure 3). Disease-free survival
was 92.4% in grade 1 tumours, 90.7% in grade 2, and 88.2%
in grade 3 tumours. Overall- and disease-speciﬁc survival
was signiﬁcantly better in grade 1 tumours versus grade 3
tumours (P = 0.009 and P = 0.11, resp.).
3.3. Therapy. Of all patients, 183 (95.8%) underwent a sur-
gical procedure. Eight patients (4.1%) did not get any form
of surgical therapy. In all records, the reason for noninvasive
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Figure 3: 5-year disease-speciﬁc survival within FIGO stage I en-
dometrioid adenocarcinoma n = 136, divided by histologic tumour
grade. Period of diagnosis 2002–2009.
management was described (2 patients died before therapy
could have been started; 5 refused therapy because of severe
comorbidity (2 of those 5 received hormonal therapy); 1
refused therapy on personal arguments).
In 178 women (97.3%), the surgical procedure was
according to national guidelines. Of allpatients that were not
treated according to the guidelines, 1 patient underwent a
BSO without hysterectomy because of massive extrauterine
extension of the tumour into the distal vagina and 4 patients
underwent a hysterectomy without the adnexa (because of
multiple adnexal adhesions (n = 2) or a vaginal procedure
(n = 2)). In all cases, the reason for not adhering to national
guidelines was documented.
3.4. Lymphadenectomy. During the study period, we did
not routinely perform a lymphadenectomy in endometrial
cancer patients unless there were palpable lymph nodes.
Three (1.7%) patients underwent a lymph node extirpation.
Allofthemhadseroustumours.Thenumberoflymphnodes
that were dissected was 1–5 nodes. All nodes were negative.
There was no additional perioperative morbidity.
From late 2009 onwards, we performed a complete
lymph node dissection in two patients with high-grade
endometrialcancer.Oneofthemhadaclearcellendometrial
carcinoma, the other a papillary serous endometrial carci-
noma. In these cases, a gynaecologic oncologist performed
the procedure (dissected lymph nodes 20–29).4 ISRN Obstetrics and Gynecology
Only the lymph nodes of the patient with the clear
cell tumour were positive (4/29). She was upgraded from
FIGO stage IC to FIGO stage IIIC and received adjuvant
radiotherapy and chemotherapy.
3.5.AdjuvantTherapy. In9cases(4.9%),adjuvantradiother-
apy was not given according to the Dutch national guidelines
of 2000. Three patients were not treated with adjuvant
radiotherapy because of severe comorbidity. One patient did
not wish to receive adjuvant therapy due to personal reasons.
Two patients died before start of adjuvant therapy. For 3
patients, there was no documented argumentation.
3.6. Recurrence. Of all recurrences (n = 22 (11.5%)), there
were local recurrences in 7 patients (31.8%), regional recur-
rences in 2 (9.1%), and newly discovered distant metastases
in 13 patients (59.1%). Most common areas for metastatic
disease were lymph nodes, lungs, abdomen, and skeleton.
In FIGO stage I disease, local recurrences were seen in 5
patients (41.7%), regional recurrences in 1 patient (8.3%),
and distant metastases in 6 patients (50.0%). In FIGO stage
II, 1 patient (50.0%) had a local recurrence and 1 (50.0%)
hadadistantmetastasis.InFIGOstageIII,6patients(75.0%)
had distant metastases and 1 patient (12.5%) developed a
local recurrence.
In FIGO stage I with adjuvant radiotherapy (n = 40),
1 patient (2.5%) developed a regional recurrence and 4
patients (10.0%) developed metastatic disease. In FIGO
stage II with adjuvant radiotherapy (n = 10), 1 patient
(10.0%) developed a local recurrence, 1 (10.0%) a regional
recurrence, and 1 (10.0%) metastatic disease. In FIGO stage
III with adjuvant radiotherapy (n = 20), 1 patient (5.0%)
developed a local recurrence, and 5 patients (25.0%) distant
metastases. Nine patients (7.1%) had recurrent disease in the
group that did not receive adjuvant radiotherapy (n = 126).
4. Discussion
A description of a cohort of patients having endometrial
cancer is not unique. The patient characteristics, tumour
characteristics, survival, and recurrence outcomes in this
study are in accordance with large (multicenter) interna-
tional studies [15–17]. Still, we consider the results of this
study very important, because the treatment of patients
having endometrial cancer is changing. This local study
will be the last before new surgical and adjuvant therapy
treatment strategies are fully implemented and the FIGO
stages have been reclassiﬁed.
A Dutch study in the same region has shown that
the incidence of endometrial cancer is increasing [18].
Besides that, the relative incidences of high-grade tumours
and serous tumours are increasing as well. The increasing
incidence of overweight patients and obesity in western
countries contributes to a higher cancer rate in general
and endometrial cancer in particular. There are many other
possible explanations why the incidence is rising, especially
in the high-grade endometrial tumours; for instance, higher
lifeexpectancy,decliningfertilityrates,andbetteravailability
of valid diagnostic procedures [19, 20]. The characteristics of
patients diagnosed and treated for endometrial cancer will
deﬁnitely change within the next few years.
Besides the changes in patients’ and tumour characteris-
tics, surgical treatment strategies have also undergone some
important changes. Since 2010, in low-grade endometrial
cancer, a laparoscopic approach is preferred to a laparotomic
surgical procedure. Also, a lymphadenectomy is believed to
be beneﬁcial in a “selective group” of patients with endome-
trial cancer [21–24]. Although there is still discussion about
thespeciﬁcgroupofpatients,theextentoftheprocedureand
its beneﬁt, it is clear that surgical treatment strategies will be
diﬀerent from now on. In our region, from 2010 onwards,
a lymphadenectomy is routinely recommended in high-
gradeendometrioid, papillaryserous,andclearcelltumours,
unless it is contraindicated due to severe comorbidity. In all
these cases, a gynaecologic oncologist has to perform this
procedure.
Aside from these changes in surgical treatment strategies,
the indications for adjuvant therapy following surgery are
also expanding. Particularly, there is a lot of ongoing
research to determine the value of and the indication for
chemotherapy or chemoradiation therapy in women with
high-risk endometrial cancer [13, 25–35].
In the very last period of inclusion for this study, we were
already routinely performing a complete lymphadenectomy.
TheFIGOstageofthispatientwasupgradedandchemother-
apy was added to the adjuvant therapy. In the future, these
changes in adjuvant treatment will have inﬂuences on the
patients’ morbidity.
Boll and coauthors have found that comorbidity
decreases the likelihood of receiving adjuvant radiotherapy
in patients with FIGO stage I endometrial cancer that
were qualiﬁed to receive adjuvant radiotherapy according
to the Dutch national guidelines [36]. It is conceivable that
the previously described changes in patients’ characteris-
tics, together with more invasive surgical treatments with
routine lymphadenectomy, the possibility of a laparoscopic
procedure and a decreased likelihood of receiving adjuvant
therapy because of severe comorbidity will make the group
of patients with endometrial cancer very heterogeneous.
Taking this into consideration, the adherence to (national)
guidelines may become less. Therefore, future studies like
t h i sw i l lb e c o m ed i ﬃcult because of the heterogeneity of the
group of patients treated for endometrial cancer.
Yet from today, all those changes will have their eﬀects
on the followup of endometrial cancer treatment. In our
opinion, it is, therefore, valuable to have the current, more
homogenous, cohort clearly described.
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